Stockreport

Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference [Yahoo! Finance]

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF 0.38 mm²/yr versus 0.59 mm²/yr for placebo (P=0.0033; AR(1) analysis P Regulatory and development progress: Belite has begun an FDA rolling submission for Stargardt af [Read more]